Cyclica, a neo-biotech headquartered in Toronto and Valence, headquartered in Montréal, recently announced entering into agreement to be acquired by Recursion, leading clinical stage TechBio company.
“Cyclica and Recursion both believe in the value of industrializing drug discovery,” said Naheed Kurji, CEO and Co-Founder of Cyclica. “Combining our proteome-wide prediction of small molecule-target interactions into Recursion’s data universe will create one of the largest fit-for-purpose biological and chemical datasets in the drug discovery space. Together, I believe Recursion will have an immense impact on human health in the years to come.”
Cyclica is an OBIO® member, participant of BDSP™ and presented at the OBIO® Investment Summit.